# ClinicalTrials.gov record NCT01263717

> PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct01263717-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01263717-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01263717-tesamorelin-v1.json
- Content SHA-256: `51b360408386408a3be623a1b12b92bc430e43984c5b4b9510703f1477fea8bb`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT01263717 ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

## Sources

<a id="source-ctg-observation-nct01263717-2017-10-30-6738333a7c13"></a>
- **ClinicalTrials.gov record NCT01263717 · retained source version 2017-10-30:6738333a7c130040e9d7e582dfa3b10b4fe72e2945cb8af1be8cf3e545162279** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01263717) (`ctg-observation-nct01263717-2017-10-30-6738333a7c13`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01263717." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01263717-tesamorelin-v1.json SHA-256: 51b360408386408a3be623a1b12b92bc430e43984c5b4b9510703f1477fea8bb.